A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
Erectile Dysfunction
About this trial
This is an interventional treatment trial for Erectile Dysfunction focused on measuring dapoxetine, premature ejaculation, ejaculation, sexual dysfunction, orgasmic disorder, sexual intercourse
Eligibility Criteria
Inclusion Criteria: Patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study diagnosis of premature ejaculation (PE) according to the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) for at least 6 months before study initiation history of intravaginal ejaculatory latency time (IELT) of <2 minutes in at least 3 out of 4 events good general health patient's partner must have a negative urine pregnancy test at time of screening Exclusion Criteria: Not taken dapoxetine or participated in another study investigating pharmacologic treatment of PE within the last 3 months no history of any medical events that are associated with the development of PE not taken another investigational drug within 1 month, or used an experimental medical device within 6 months, of study initiation no positive diagnosis of depressive or anxiety disorder, manic episode, panic disorder, obsessive-compulsive disorder, posttraumatic stress disorder, alcohol abuse and dependence, schizophrenia, or other psychotic disorders no known allergy or hypersensitivity to selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)